Healthcare / Medical DistributionTokyo
$820.00
-20.00 (-2.38%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $-3.9M · quality 31.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.9B
P/E
111.1x
↑EV/EBITDA
0.2x
↓ROE
2.7%
↑Gross Margin
12.8%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-10.3%
FCF CAGR
—
FCF margin
-0.8%
FCF / Net income
-1.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $21.49B · net income $152.8M · FCF $-168.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $21.49B | $21.49B | $19.80B | $26.63B | $29.77B |
| Net Income | $152.8M | $152.8M | $136.1M | $271.3M | $437.1M |
| EBITDA | $378.0M | $378.0M | $277.6M | $536.9M | $787.1M |
| EPS | — | — | 22.96 | 45.84 | 73.84 |
| Gross Margin | 12.8% | 12.8% | 13.2% | 10.6% | 10.3% |
| Operating Margin | 1.3% | 1.3% | 0.9% | 1.7% | 2.2% |
| Net Margin | 0.7% | 0.7% | 0.7% | 1.0% | 1.5% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | — | 0.02 |
| Current Ratio | 1.39 | 1.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-168.8M | $-168.8M | $-3.9M | $258.4M | $195.5M |
| Returns | |||||
| ROE | 2.7% | 2.7% | 2.4% | 4.9% | 8.1% |
| Valuation | |||||
| P/E | 111.11 | 111.11 | 43.55 | 19.52 | 10.47 |
| EV/EBITDA | 0.21 | 0.21 | 1.27 | -0.45 | -1.03 |
| P/B | 0.86 | 0.86 | 1.06 | 0.95 | 0.85 |
| Growth & Yield | |||||
| Revenue Growth | 8.5% | 8.5% | -25.6% | -10.5% | — |
| EPS Growth | — | — | -49.9% | -37.9% | — |
| Dividend Yield | 2.1% | 2.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-21.0%
Start / end P/E
n/dx → n/dx
EPS bridge
22.96 → n/d
Residual
-23.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.